Key result
Trastuzumab abrogates hCDC functional benefits in infarcted mouse hearts, worsening ejection fraction and scar thickness.
Why the study?
Trastuzumab cardiotoxicity may involve inhibition of human adult cardiac-derived stem cells in addition to direct adverse effects on cardiomyocytes.
Does Trastuzumab impair the regenerative function of human resident cardiac stem cells?
Does Trastuzumab impair the regenerative function of human resident cardiac stem cells?
Answers are grounded in this paper and cite their sources.
Trastuzumab impairs the cardiomyogenic and angiogenic capacities of human resident cardiac stem cells, providing a potential novel mechanism for its cardiotoxicity.
Trastuzumab (TZM), a monoclonal antibody against the ERBB2 protein, increases survival in ERBB2-positive breast cancer patients. Its clinical use, however, is limited by cardiotoxicity. We sought to evaluate whether TZM cardiotoxicity involves inhibition of human adult cardiac-derived stem cells, in addition to previously reported direct adverse effects on cardiomyocytes. To test this idea, we exposed human cardiosphere-derived cells (hCDCs), a natural mixture of cardiac stem cells and supporting cells that has been shown to exert potent regenerative effects, to TZM and tested the effects in vitro and in vivo. We found that ERBB2 mRNA and protein are expressed in hCDCs at levels comparable to those in human myocardium. Although clinically relevant concentrations of TZM had no effect on proliferation, apoptosis, or size of the c-kit-positive hCDC subpopulation, in vitro assays demonstrated diminished potential for cardiogenic differentiation and impaired ability to form microvascular networks in TZM-treated cells. The functional benefit of hCDCs injected into the border zone of acutely infarcted mouse hearts was abrogated by TZM: infarcted animals treated with TZM + hCDCs had a lower ejection fraction, thinner infarct scar, and reduced capillary density in the infarct border zone compared with animals that received hCDCs alone (n = 12 per group). Collectively, these results indicate that TZM inhibits the cardiomyogenic and angiogenic capacities of hCDCs in vitro and abrogates the morphological and functional benefits of hCDC transplantation in vivo. Thus, TZM impairs the function of human resident cardiac stem cells, potentially contributing to TZM cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Barth et al. (2012) studied Cardiotoxicity (n=24). Trastuzumab vs. hCDCs alone was evaluated on Ejection fraction, infarct scar thickness, and capillary density. Trastuzumab abrogated the functional benefits of human cardiosphere-derived cells in acutely infarcted mouse hearts (n=12 per group), resulting in lower ejection fraction and thinner infarct scar.
Synapse has enriched 10 related papers. Consider them for comparative context: